Association of the Charlson comorbidity index with mortality in systemic lupus erythematosus

Arthritis Care and Research

Volumn 63, Issue 9, 2011, Pages 1233-1237

  Jonsen A ^a   Clarke, A E ^a   Joseph, L ^a   Belisle, P ^a   Bernatsky, S ^a   Nived, O ^b   Bengtsson, A A ^b   Sturfelt, G ^b   Pineau, C A ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE HEART INFARCTION; ADOLESCENT; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTHRITIS; ARTICLE; CANADA; CHARLSON COMORBIDITY INDEX; CHRONIC LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; DEMENTIA; DISCOID LUPUS ERYTHEMATOSUS; DISEASE ACTIVITY; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; HAZARD RATIO; HEALTH SURVEY; HEMIPLEGIA; HUMAN; INFLAMMATION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOUTH ULCER; PERIPHERAL VASCULAR DISEASE; PHOTOSENSITIVITY; RASH; RISK ASSESSMENT; RUTABAGA; SEIZURE; SYSTEMIC LUPUS ERYTHEMATOSUS; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS INDICATORS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUEBEC; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TIME FACTORS; YOUNG ADULT;

EID: 80052304210     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20506     Document Type: Article

References (28)

1. Stahl-Hallengren C, Jonsen A, Nived O, Sturfelt G,. Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 2000; 27: 685-91. (Pubitemid 30151347)
2. Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT,. Mortality studies in systemic lupus erythematosus: results from a single center. III. Improved survival over 24 years. J Rheumatol 1997; 24: 1061-5. (Pubitemid 27250109)
3. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J,. Mortality studies in systemic lupus erythematosus: results from a single center. II. Predictor variables for mortality. J Rheumatol 1995; 22: 1265-70.
4. Seleznick MJ, Fries JF,. Variables associated with decreased survival in systemic lupus erythematosus. Semin Arthritis Rheum 1991; 21: 73-80.
5. Mok CC, Lee KW, Ho CT, Lau CS, Wong RW,. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford) 2000; 39: 399-406. (Pubitemid 30307326)
6. Ginzler EM, Diamond HS, Weiner M, Schlesinger M, Fries JF, Wasner C, et al. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum 1982; 25: 601-11. (Pubitemid 12078972)
7. Swaak AJ, Nossent JC, Bronsveld W, Van Rooyen A, Nieuwenhuys EJ, Theuns L, et al. Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989; 48: 447-54. (Pubitemid 19158930)
8. Ibanez D, Gladman DD, Urowitz MB,. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 2005; 32: 824-7. (Pubitemid 40676490)
9. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
10. Ward MM, Pyun E, Studenski S,. Long-term survival in systemic lupus erythematosus: patient characteristics associated with poorer outcomes. Arthritis Rheum 1995; 38: 274-83.
11. Alarcon GS, McGwin G Jr, Bastian HM, Roseman J, Lisse J, Fessler BJ, et al, for the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups VII [correction of VIII]: predictors of early mortality in the LUMINA cohort. Arthritis Rheum 2001; 45: 191-202. (Pubitemid 32954446)
12. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-9. (Pubitemid 26085211)
13. Nived O, Jonsen A, Bengtsson AA, Bengtsson C, Sturfelt G,. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for survival in systemic lupus erythematosus. J Rheumatol 2002; 29: 1398-400. (Pubitemid 34755603)
14. Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS,. Early damage as measured by the SLICC/ACR Damage Index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001; 10: 93-6. (Pubitemid 32410092)
15. Becker-Merok A, Nossent HC,. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol 2006; 33: 1570-7. (Pubitemid 44168829)
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83. (Pubitemid 17055592)
17. De Groot V, Beckerman H, Lankhorst GJ, Bouter LM,. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003; 56: 221-9. (Pubitemid 36513483)
18. Hall WH, Jani AB, Ryu JK, Narayan S, Vijayakumar S,. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis 2005; 8: 22-30.
19. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004; 104: 961-8. (Pubitemid 39038014)
20. Paleri V, Wight RG,. Applicability of the adult comorbidity evaluation-27 and the Charlson indexes to assess comorbidity by notes extraction in a cohort of United Kingdom patients with head and neck cancer: a retrospective study. J Laryngol Otol 2002; 116: 200-5. (Pubitemid 34214430)
21. Thombs BD, Singh VA, Halonen J, Diallo A, Milner SM,. The effects of preexisting medical comorbidities on mortality and length of hospital stay in acute burn injury: evidence from a national sample of 31,338 adult patients. Ann Surg 2007; 245: 629-34. (Pubitemid 46555668)
22. Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Desideri CM, et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006; 22: 477-82. (Pubitemid 44774052)
23. Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G,. Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology 2008; 70: 1423-30. (Pubitemid 351521935)
24. Ward MM,. Development and testing of a systemic lupus-specific risk adjustment index for in-hospital mortality. J Rheumatol 2000; 27: 1408-13. (Pubitemid 30354036)
25. Jonsson H, Nived O, Sturfelt G,. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 1989; 68: 141-50. (Pubitemid 19132411)
26. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7. (Pubitemid 13221242)
27. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
28. Ibanez D, Urowitz MB, Gladman DD,. Summarizing disease features over time. I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol 2003; 30: 1977-82. (Pubitemid 37075547)